112 -4 (32/3) 2020 — Kityan S.A., Badalbaeva N.M., — AT I RECEPTOR BLOCKERS (ARBs) — DRUGS OF CHOICE IN THE THERAPY OF ADVERSE REACTIONS MANIFESTING ARTERIAL HYPERTENSION ON THE BACKGROUND OF LONG-TERM ADMISSION OF AMINOGLYCOSIDES OF ULEMEKULA BOLECULATURES
AT I RECEPTOR BLOCKERS (ARBs) – DRUGS OF CHOICE IN THE THERAPY OF ADVERSE REACTIONS MANIFESTING ARTERIAL HYPERTENSION ON THE BACKGROUND OF LONG-TERM ADMISSION OF AMINOGLYCOSIDES OF ULEMEKULA BOLECULATURES
Kityan S.A. -Andijan State Medical Institute.
Badalbaeva N.M. -Andijan State Medical Institute.
Yusupova M.SH. –Andijan State Medical Institute.
Musashaykhov U.Kh. –Andijan State Medical Institute.
Resume
Cardiovascular morbidity (CVD) and mortality (CVD) are closely related to arterial hypertension (AH), the control of which is one of the most important medical problems. In recent years, there have been significant changes in the definition of approaches to the diagnosis and treatment of arterial hypertension (AH).
Immunity is a specific reactivity, a way of protecting the body from living bodies and substances that carry signs of genetic foreignness; the ability of higher organisms to recognize, neutralize and eliminate genetically foreign substances; function of the specialized system of genetic surveillance of the body – the immune system
When an active tuberculous process is combined with cardiovascular pathology, great difficulties arise due to the need for complex antibiotic therapy for tuberculosis and the simultaneous treatment of concomitant diseases, including vascular pathology.
Key words: tuberculosis, ethambutol, arterial hypertension, antihypertensive drugs.
First page
436
Last page
437
For citation: Kityan S.A., Badalbaeva N.M., Yusupova M. SH., Musashaykhov U.Kh. At i receptor blockers (arbs) – drugs of choice in the therapy of adverse reactions manifesting arterial hypertension on the background of long-term admission of aminoglycosides of ulemekula boleculatures//New Day in Medicine 4(32)2020 436-437 https://cutt.ly/Hz2U95G
List of References
- Кобалава Ж.Д., Толкачева В.В. Цереброваскулярные осложнения АГ. //Возможности антагонистов рецепторов ангиотензина II. Сердце, т. 2, № 4, 2013, стр.165-172.
- Лазебник Л.Б., Милюкова О.М., Комиссаренко И.А. Блокаторы рецепторов ангиотензина II. /Москва, 2011, 56 с.
- Stephen S.C., Pershadsingh H.A., Ho C.I. et al. Identification of telmisartan as f unique angiotensin II receptor antagonist with selective PRAR? -modulating activity. //Hypertension, vol. 43, 5, p2012..993-998.
- Lucius R., Galliant S., Busche S. Et al. Beyond blood pressure: new roles for angiotensin II. //Cell Mol Life Sci vol. 56, 1999, p. 1008-1019.
- Unger T. Blood pressure lowering and rennin angiotensin system blockade. //J. Hypertens, Vol.21, suppl. 6, 2003, p. S3-7.